Human placenta mesenchymal stem cells-derived extracellular vesicles regulate collagen deposition in intestinal mucosa of mice with colitis

doi:10.3969/j.issn.2095-4344.2167

Abstract

Abstract: BACKGROUND:Intestinal fibrosis is a common complication in inflammatory bowel disease and leads to functional damage and intestinal obstruction. Intestinal fibrosis is mainly related to the imbalance of deposition and degradation of extracellular matrix components, such as collagens and fibronectins. Studies have found that mesenchymal stem cells secreted soluble bioactive substance such as extracellular vesicles via paracrine action, which exerted marked anti-fibrosis effect.

OBJECTIVE: To investigate the effect of human placenta mesenchymal stem cells-derived extracellular vesicles on collagen deposition in mice with colitis.

METHODS: Totally 24 BALB/c mice were randomly divided into sham operation group, model group and extracellular vesicles group, with 8 mice in each group. Except the sham operation group, the remaining mice of model group and extracellular vesicles group were treated with trinitro-benzene-sulfonic acid to induce intestinal fibrosis, once a day for 6 weeks. The mice in the extracellular vesicles group and model group were administered with extracellular vesicles and phosphate-buffered saline, respectively, at 3 weeks, once a day for 6 weeks. The therapeutic effect of extracellular vesicles was evaluated by disease active index score and the colon weight/length ratio at 1-7 weeks. Diseased intestinal segment was subjected to histological staining. Western blot assay and RT-PCR were used to measure fibrosis related indicators so as to evaluate the degree of intestinal fibrosis.
RESULTS AND CONCLUSION: (1) Compared with the model group, disease active index score and the colon weight/length ratio were significantly reduced, and colonic pathology was significantly improved in the extracellular vesicles group. (2) Compared with the model group, collagen deposition in colon mucosa of mice was significantly reduced, and the expression of collagen I, collagen III and transforming growth factor-β1 decreased significantly in the extracellular vesicles group. (3) Compared with the model group, expression levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 in mouse colon tissue were significantly increased, while the expression level of tissue inhibitor of metalloproteinase 1 was decreased in the extracellular vesicles group. (4) Results suggest that human placenta mesenchymal stem cells-derived extracellular vesicles can obviously improve the severity of colon injury and reduce the collagen deposition of intestinal mucosa in mice with enteritis.

Key words: stem cells, human placenta mesenchymal stem cells, extracellular vesicles, inflammatory bowel disease, intestinal fibrosis, collagen, experiment, mice

CLC Number:

Duan Liyun, Cao Xiaocang. Human placenta mesenchymal stem cells-derived extracellular vesicles regulate collagen deposition in intestinal mucosa of mice with colitis[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(7): 1026-1031.

Figures/Tables 6

References

[1] WEIMERS P, MUNKHOLM P. The Natural History of IBD: Lessons Learned. Curr Treat Options Gastroenterol. 2018;16(1):101-111.
[2] FIOCCHI C, LUND PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G677-683.
[3] PALLONE F, MONTELEONE G. Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol. 2001;17(4):307-312.
[4] ZORZI F, CALABRESE E, MONTELEONE G. Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn’s disease. Clin Sci (Lond). 2015;129(12):1107-1113.
[5] LATELLA G, DI GREGORIO J, FLATI V, et al. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol. 2015;50(1): 53-65.
[6] LI J, MAO R, KURADA S, et al. Pathogenesis of fibrostenosing Crohn’s disease. Transl Res. 2019;209:39-54.
[7] RIEDER F, FIOCCHI C, ROGLER G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2): 340-350.e6.
[8] LOEUILLARD E, BERTRAND J, HERRANEN A, et al. 2,4,6-trinitrobenzene sulfonic acid-induced chronic colitis with fibrosis and modulation of TGF-β1 signaling. World J Gastroenterol. 2014;20(48):18207-18215.
[9] DI SABATINO A, JACKSON CL, PICKARD KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut. 2009;58(6):777-789.
[10] BETTENWORTH D, RIEDER F. Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication. Dig Dis. 2017;35(1-2):25-31.
[11] MEIJER MJ, MIEREMET-OOMS MA, VAN DER ZON AM, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn’s disease phenotype. Dig Liver Dis. 2007;39(8):733-739.
[12] EL AGHA E, KRAMANN R, SCHNEIDER RK, et al. Mesenchymal Stem Cells in Fibrotic Disease. Cell Stem Cell. 2017;21(2):166-177.
[13] VOSWINKEL J, FRANCOIS S, SIMON JM, et al. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):180-192.
[14] CAMUSSI G, DEREGIBUS MC, CANTALUPPI V. Role of stem-cell-derived microvesicles in the paracrine action of stem cells. Biochem Soc Trans. 2013; 41(1):283-287.
[15] VAN NIEL G, D’ANGELO G, RAPOSO G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228.
[16] SHOJAATI G, KHANDAKER I, FUNDERBURGH ML, et al. Mesenchymal Stem Cells Reduce Corneal Fibrosis and Inflammation via Extracellular Vesicle-Mediated Delivery of miRNA. Stem Cells Transl Med. 2019;8(11):1192-1201.
[17] LAWRANCE IC, WU F, LEITE AZ, et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology. 2003;125(6):1750-1761.
[18] MURTHY SN, COOPER HS, SHIM H, et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993; 38(9):1722-1734.
[19] CHOI YJ, KOO JB, KIM HY, et al. Umbilical cord/placenta-derived mesenchymal stem cells inhibit fibrogenic activation in human intestinal myofibroblasts via inhibition of myocardin-related transcription factor A. Stem Cell Res Ther. 2019;10(1):291.
[20] LI T, YAN Y, WANG B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22(6): 845-854.
[21] BIANCONE L, BRUNO S, DEREGIBUS MC, et al. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant. 2012;27(8): 3037-3042.
[22] BURRELLO J, MONTICONE S, GAI C, et al. Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Front Cell Dev Biol. 2016;4:83.
[23] WANG B, YAO K, HUUSKES BM, et al. Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis. Mol Ther. 2016;24(7):1290-1301.
[24] LOU G, CHEN Z, ZHENG M, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med. 2017;49(6):e346.
[25] MARDPOUR S, GHANIAN MH, SADEGHI-ABANDANSARI H, et al. Hydrogel-Mediated Sustained Systemic Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles Improves Hepatic Regeneration in Chronic Liver Failure. ACS Appl Mater Interfaces. 2019;11(41):37421-37433.
[26] FANG S, XU C, ZHANG Y, et al. Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomal MicroRNAs Suppress Myofibroblast Differentiation by Inhibiting the Transforming Growth Factor-β/SMAD2 Pathway During Wound Healing. Stem Cells Transl Med. 2016;5(10): 1425-1439.
[27] BIER A, BERENSTEIN P, KRONFELD N, et al. Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy. Biomaterials. 2018;174:67-78.
[28] DOEPPNER TR, HERZ J, GÖRGENS A, et al. Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression. Stem Cells Transl Med. 2015;4(10):1131-1143.
[29] QI X, ZHANG J, YUAN H, et al. Exosomes Secreted by Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Repair Critical-Sized Bone Defects through Enhanced Angiogenesis and Osteogenesis in Osteoporotic Rats. Int J Biol Sci. 2016;12(7):836-849.
[30] GARCÍA-OLMO D, GARCÍA-ARRANZ M, GARCÍA LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18(5):451-454.
[31] CARVELLO M, LIGHTNER A, YAMAMOTO T, et al. Mesenchymal Stem Cells for Perianal Crohn’s Disease. Cells. 2019;8(7). pii: E764.
[32] PHINNEY DG, PITTENGER MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells. 2017;35(4):851-858.
[33] QIU G, ZHENG G, GE M, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018;9(1):320.
[34] KESHTKAR S, AZARPIRA N, GHAHREMANI MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther. 2018;9(1):63.
[35] HONG P, YANG H, WU Y, et al. The functions and clinical application potential of exosomes derived from adipose mesenchymal stem cells: a comprehensive review. Stem Cell Res Ther. 2019;10(1):242.
[36] TKACH M, THÉRY C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. Cell. 2016;164(6):1226-1232.
[37] RIEDER F, FIOCCHI C. Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis. 2013;31(2):186-193.